|
WO2020263995A1
|
|
Hydroxamic acids comprising pyrazole moiety and uses thereof
|
|
AU2019236463A1
|
|
Pyridin-2-yl alkylamino substituted hydroxamic acid and uses thereof
|
|
EP3684406A1
|
|
Filovirus vaccine and methods of use
|
|
EP3490595A1
|
|
Optimized zika virus envelope gene and expression thereof
|
|
US2019298819A1
|
|
West nile virus vaccine and method of use thereof
|
|
WO2016168483A1
|
|
Hydroxamic acids and uses thereof
|
|
CN102481355A
|
|
Recombinant subunit west nile virus vaccine for protections of human subjects
|
|
US2007042001A1
|
|
Influenza recombinant subunit vaccine
|
|
US2008213318A1
|
|
Malaria MSP-1 C-terminal enhanced subunit vaccine
|
|
WO2006119168A2
|
|
Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors
|
|
WO2006119125A2
|
|
Methods for synthesis of carotenoids, including analogs, derivatives, and synthetic and biological intermediates
|
|
WO2006102576A1
|
|
Water-dispersible carotenoids, including analogs and derivatives
|
|
US2005287170A1
|
|
Subunit vaccine against West Nile viral infection
|
|
AU2003300831A8
|
|
Recombinant vaccine against flavivirus infection
|
|
CN1708480A
|
|
Carotenoid analogs for the inhibition and amelioration of disease
|
|
AU2002300271B2
|
|
Recombinant dimeric envelope vaccine against flaviviral infection
|
|
EP1326625A1
|
|
Immunogenic composition of hepatitis c and methods of use thereof
|
